| Elise Johanson Doll, CNM | |
|
1200 Old York Rd, Abington, PA 19001-3720 | |
| (215) 481-2000 | |
| Not Available |
| Full Name | Elise Johanson Doll |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 5 Years |
| Location | 1200 Old York Rd, Abington, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336775931 | NPI | - | NPPES |
| MW010570 | Other | PA | CNM LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | MW010570 (Pennsylvania) | Secondary |
| 367A00000X | Advanced Practice Midwife | 25ME00071401 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Abington Memorial Hospital | 3274437736 | 528 |
News Archive
A newly developed test appears highly accurate in identifying newborns with fragile X syndrome—the most common inherited cause of cognitive impairment—as well as identifying couples who are carriers of the causative gene, reports a study in the March issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
In a study published in Nature Genetics today, a team of scientists at The Institute of Cancer Research have discovered a gene that may hold clues to the development of many cases of the most common cancers including lung, breast, prostate and colon cancers.
Using an experimental positron emission tomography scan, researchers have found elevated amounts of abnormal tau protein in brain regions players with cognitive, mood and behavior symptoms.
› Verified 1 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1316189855 PECOS PAC ID: 3274437736 Enrollment ID: O20091218000204 |
News Archive
A newly developed test appears highly accurate in identifying newborns with fragile X syndrome—the most common inherited cause of cognitive impairment—as well as identifying couples who are carriers of the causative gene, reports a study in the March issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
In a study published in Nature Genetics today, a team of scientists at The Institute of Cancer Research have discovered a gene that may hold clues to the development of many cases of the most common cancers including lung, breast, prostate and colon cancers.
Using an experimental positron emission tomography scan, researchers have found elevated amounts of abnormal tau protein in brain regions players with cognitive, mood and behavior symptoms.
› Verified 1 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366835571 PECOS PAC ID: 3274437736 Enrollment ID: O20150624002498 |
News Archive
A newly developed test appears highly accurate in identifying newborns with fragile X syndrome—the most common inherited cause of cognitive impairment—as well as identifying couples who are carriers of the causative gene, reports a study in the March issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
In a study published in Nature Genetics today, a team of scientists at The Institute of Cancer Research have discovered a gene that may hold clues to the development of many cases of the most common cancers including lung, breast, prostate and colon cancers.
Using an experimental positron emission tomography scan, researchers have found elevated amounts of abnormal tau protein in brain regions players with cognitive, mood and behavior symptoms.
› Verified 1 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366985566 PECOS PAC ID: 3274437736 Enrollment ID: O20170221001005 |
News Archive
A newly developed test appears highly accurate in identifying newborns with fragile X syndrome—the most common inherited cause of cognitive impairment—as well as identifying couples who are carriers of the causative gene, reports a study in the March issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
In a study published in Nature Genetics today, a team of scientists at The Institute of Cancer Research have discovered a gene that may hold clues to the development of many cases of the most common cancers including lung, breast, prostate and colon cancers.
Using an experimental positron emission tomography scan, researchers have found elevated amounts of abnormal tau protein in brain regions players with cognitive, mood and behavior symptoms.
› Verified 1 days ago
| Entity Name | Abington Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1548825243 PECOS PAC ID: 3274437736 Enrollment ID: O20190723002404 |
News Archive
A newly developed test appears highly accurate in identifying newborns with fragile X syndrome—the most common inherited cause of cognitive impairment—as well as identifying couples who are carriers of the causative gene, reports a study in the March issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
In a study published in Nature Genetics today, a team of scientists at The Institute of Cancer Research have discovered a gene that may hold clues to the development of many cases of the most common cancers including lung, breast, prostate and colon cancers.
Using an experimental positron emission tomography scan, researchers have found elevated amounts of abnormal tau protein in brain regions players with cognitive, mood and behavior symptoms.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elise Johanson Doll, CNM 1200 Old York Rd, Abington, PA 19001-3788 Ph: (215) 481-2000 | Elise Johanson Doll, CNM 1200 Old York Rd, Abington, PA 19001-3720 Ph: (215) 481-2000 |
News Archive
A newly developed test appears highly accurate in identifying newborns with fragile X syndrome—the most common inherited cause of cognitive impairment—as well as identifying couples who are carriers of the causative gene, reports a study in the March issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
In a study published in Nature Genetics today, a team of scientists at The Institute of Cancer Research have discovered a gene that may hold clues to the development of many cases of the most common cancers including lung, breast, prostate and colon cancers.
Using an experimental positron emission tomography scan, researchers have found elevated amounts of abnormal tau protein in brain regions players with cognitive, mood and behavior symptoms.
› Verified 1 days ago
Yacoba Zwennes, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1245 Highland Ave Ste 109, Abington, PA 19001 Phone: 215-481-4211 | |
Julianna Choi, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 | |
Jameer Weldon, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-2000 |